The estimated Net Worth of Connie Matsui is at least $16.2 million dollars as of 5 November 2021. Ms. Matsui owns over 32,000 units of Halozyme Therapeutics stock worth over $10,807,970 and over the last 21 years she sold HALO stock worth over $5,055,680. In addition, she makes $305,002 as Independent Chairman of the Board at Halozyme Therapeutics.
Sign up
Ms. Matsui HALO stock SEC Form 4 insiders trading
Connie has made over 16 trades of the Halozyme Therapeutics stock since 2003, according to the Form 4 filled with the SEC. Most recently she sold 32,000 units of HALO stock worth $1,292,160 on 5 November 2021.
The largest trade she's ever made was selling 80,000 units of Halozyme Therapeutics stock on 12 July 2005 worth over $2,897,600. On average, Connie trades about 10,264 units every 115 days since 2003. As of 5 November 2021 she still owns at least 181,983 units of Halozyme Therapeutics stock.
You can see the complete history of Ms. Matsui stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Connie Matsui biography
Connie L. Matsui is Independent Chairman of the Board of the Company. Ms. Matsui brings to our Board over 18 years of general management experience in the biotechnology industry. She retired from Biogen Idec Inc. in January 2009 as the Executive Vice President, Knowledge and Innovation Networks. She served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. Among the major roles she played after joining IDEC Pharmaceuticals in November 1992 were: Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning; Collaboration Chair for the late stage development and commercialization of rituximab (tradenames: Rituxan® and MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui has been active on a number of not-for-profit boards and served as National President/Board Chair of the Girl Scouts of the USA from 1999 to 2002. Ms. Matsui serves on the board of directors biopharmaceutical companies Artelo Biosciences, Inc. and Sutro Biopharma, Inc. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University.
What is the salary of Connie Matsui?
As the Independent Chairman of the Board of Halozyme Therapeutics, the total compensation of Connie Matsui at Halozyme Therapeutics is $305,002. There are 4 executives at Halozyme Therapeutics getting paid more, with Helen Torley having the highest compensation of $5,857,130.
How old is Connie Matsui?
Connie Matsui is 66, she's been the Independent Chairman of the Board of Halozyme Therapeutics since 2016. There are no older and 10 younger executives at Halozyme Therapeutics.
What's Connie Matsui's mailing address?
Connie's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Halozyme Therapeutics
Over the last 17 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay et Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
What does Halozyme Therapeutics do?
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
What does Halozyme Therapeutics's logo look like?
Complete history of Ms. Matsui stock trades at Biogen Inc, Halozyme Therapeutics, Sutro Biopharma Inc et Artelo Biosciences Inc
Halozyme Therapeutics executives and stock owners
Halozyme Therapeutics executives and other stock owners filed with the SEC include:
-
Helen Torley,
President, Chief Executive Officer, Director -
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.,
Pres, CEO & Director -
Elaine D. Sun,
Sr. VP & CFO -
Dr. Michael J. LaBarre,
Sr. VP & Chief Technical Officer -
Connie Matsui,
Independent Chairman of the Board -
Jeffrey Henderson,
Independent Director -
Kenneth Kelley,
Independent Director -
Matthew Posard,
Independent Director -
Bernadette Connaughton,
Independent Director -
Jean-Pierre Bizzari,
Independent Director -
James Daly,
Independent Director -
Al Kildani,
Vice President, Investor Relations & Corporate Communications -
Elaine Sun,
Chief Financial Officer, Senior Vice President -
Todd Butler,
Chief of Staff to the CEO, VP & Head of Project Management -
Dr. Steve Knowles B.S.,
Chief Medical Officer -
William J. Fallon,
Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances -
Amy Marinne Fox,
VP of HR -
Mark Snyder,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Albert S. Kildani,
VP of Investor Relations & Corp. Communications -
Ed Gemo,
VP, Chief Information & Security Officer -
Athena Countouriotis,
SVP and Chief Medical Officer -
Kathryn E Falberg,
Director -
Mark J Gergen,
SVP, Chief Operating Officer -
Mark Howard Snyder,
SVP, CHIEF LEGAL OFFICER -
Randal J Kirk,
Director -
Harry J Leonhardt,
SVP, GC and CCO -
Alison A. Armour,
SVP, Research & Development -
John Stuart Patton,
Director -
Robert Engler,
Director -
David A Ramsay,
Secretary, CFO -
William J Fallon,
VP-Manufacturing and Operation -
James P Shaffer,
VP & Chief Commercial Officer -
Jean I Liu,
VP & General Counsel -
Gregory Ian Frost,
VP and Chief Scientific Off. -
H. Michael Shepard,
VP, Chief Scientific Officer -
Kurt A Gustafson,
Vice President and CFO -
Steven T Thornton,
Director -
Jonathan E Lim,
President, CEO -
Richard C Yocum,
VP-Clinical Development -
Jonathan A Leff,
VP, Chief Medical Officer -
Robert J Little,
VP-Chief Commercial Officer -
Don A Kennard,
Vice President, Regulatory Aff -
Matthew Hooper,
Vice Pres & General Counsel -
Benjamin Hickey,
SVP, Chief Commerical Officer -
Laurie Stelzer,
SVP, Chief Financial Officer -
Mahesh Krishnan,
-
Masaru Matsuda,
SVP, General Counsel -
Akiko Moni Miyashita,
-
Michael J. La Barre,
SVP, CHIEF TECHNICAL OFFICER -
Nicole La Brosse,
SVP, CHIEF FINANCIAL OFFICER -
Barbara Gayle Duncan,